Julian Engel

发表

Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34.

H. Waldmann, H. Osada, D. Rauh, 2017, Angewandte Chemie.

Identification and further development of potent TBK1 inhibitors.

Roman K. Thomas, D. Rauh, H. Balke-Want, 2015, ACS chemical biology.

Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.

J. Hengstler, C. Schultz-Fademrecht, D. Rauh, 2017, Journal of medicinal chemistry.

A review of a decade of lessons from one of the world’s largest MPAs: conservation gains and key challenges

G. Hays, J. Mortimer, F. Micheli, 2020, Marine Biology.

Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7).

D. Rauh, Jonas Lategahn, Julian Engel, 2019, Journal of medicinal chemistry.

Characterization of Covalent-Reversible EGFR Inhibitors

D. Rauh, Julian Engel, Debjit Basu, 2017, ACS omega.

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.

S. Laufer, D. Rauh, Jonas Lategahn, 2017, Journal of medicinal chemistry.

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S† †Electronic supplementary information (ESI) available. CCDC 1876852. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9sc03445e

J. Hengstler, R. Zahedi, L. Kollipara, 2019, Chemical science.

Identification of type II and III DDR2 inhibitors.

H. Nguyen, T. Phan, C. Grütter, 2014, Journal of medicinal chemistry.

Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer.

Julian Engel, Daniel Rauh, D. Rauh, 2016, ACS medicinal chemistry letters.

Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer

K. Shokat, Roman K. Thomas, M. Peifer, 2017 .

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors

K. Shokat, Roman K. Thomas, M. Peifer, 2017, Science Translational Medicine.

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.

Jochen Heil, Franziska Hoffgaard, Julian Engel, 2015, Journal of medicinal chemistry.

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.

C. Schultz-Fademrecht, D. Rauh, S. Bauer, 2017, Journal of medicinal chemistry.

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR.

R. Zahedi, L. Kollipara, C. Schultz-Fademrecht, 2016, Angewandte Chemie.

A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening

B. Klebl, R. Reinscheid, M. Baumann, 2022, bioRxiv.

11th German Conference on Chemoinformatics (GCC 2015)

Timothy Clark, Jonathan W. Essex, Peter Kolb, 2016, J. Cheminformatics.

Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.

J. Penninger, S. Cronin, D. Rauh, 2019, Journal of medicinal chemistry.

Characterization of Covalent Pyrazolopyrimidine–MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7)

D. Rauh, Jonas Lategahn, Julian Engel, 2019 .